3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
4
Endocrine
4
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
CNS
1
Conditions
Small Cell Lung Carcinoma
13
Carcinoma, Non-Small-Cell Lung
10
Lung Neoplasms
9
Stomach Neoplasms
3
Ovarian Neoplasms
3
Mesothelioma
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Thymoma
1
SCLC,Extensive Stage
1
SCLC
1
Prostatic Neoplasms
1
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
1
Non-small-cell Lung Cancer Patients
1
Non-small Cell Lung Cancer NSCLC
1
Non-small Cell Lung Cancer Metastatic
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Melanoma
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
EGFR-Mutated Non-Small-Cell Lung Carcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Advanced Solid Tumor
1
Interventions
Nivolumab
3
Cyclophosphamide
3
pembrolizumab
2
fludarabine phosphate
2
fludarabine
2
Paclitaxel
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
Fluorodeoxyglucose F18
2
Everolimus
2
Carboplatin
2
tislelizumab
1
taxane
1
surufatinib
1
romidepsin
1
repotrectinib
1
pralsetinib
1
olaparib
1
liposomal doxorubicin
1
entrectinib
1
cabozantinib
1
atezolizumab
1
alectinib
1
aldesleukin
1
Vinorelbine
1
Temozolomide
1
Specimen Handling
1
RRx-001
1
Quality of Life
1
Pemetrexed
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
olaparib
×
Thoracic
×
Clear all
NCT04375267
2026-04-14
LuPARP
Vastra Gotaland Region
Phase 1
Completed
18 enrolled